The Drug Controller General of India had accorded its approval to Venus Remedies for launch of the fourth product developed by Venus Research Center, after completion of its multi-centered Phase III clinical trials and all related studies in March 2008.
Tobracef, a brand launched by the marketing division of the company, is reported to be a solution for the treatment of life-threatening infections caused by Pseudomonas aeruginosa/methicillin resistant Staphylococcus aureus in APE/cystic fibrosis patients.